CAYMAN CHEMICAL COMPANY Non-Antibody Products — page 1 of 1
Non-Antibody Products
Page 1,143 of 1,297
| Name | Description | Size | Catalog # | |
|---|---|---|---|---|
| SR 144528 | A CB2 receptor antagonist (Ki = 0.6 nM); selective for CB2 over CB1 recept… | 50 mg | 9000491-50 | More Info |
| SR 16584 | An antagonist of the α3β4 nicotinic acetylcholine receptor subt… | 1 mg | 10683-1 | More Info |
| SR 16584 | An antagonist of the α3β4 nicotinic acetylcholine receptor subt… | 10 mg | 10683-10 | More Info |
| SR 16584 | An antagonist of the α3β4 nicotinic acetylcholine receptor subt… | 5 mg | 10683-5 | More Info |
| SR 1664 | A small molecule that blocks phosphorylation of PPARγ by Cdk5 (IC50… | 1 mg | 11086-1 | More Info |
| SR 1664 | A small molecule that blocks phosphorylation of PPARγ by Cdk5 (IC50… | 10 mg | 11086-10 | More Info |
| SR 1664 | A small molecule that blocks phosphorylation of PPARγ by Cdk5 (IC50… | 25 mg | 11086-25 | More Info |
| SR 1664 | A small molecule that blocks phosphorylation of PPARγ by Cdk5 (IC50… | 5 mg | 11086-5 | More Info |
| SR 16832 | A dual-site covalent antagonist of PPARγ; inhibits MRL20-induced all… | 1 mg | 27632-1 | More Info |
| SR 16832 | A dual-site covalent antagonist of PPARγ; inhibits MRL20-induced all… | 10 mg | 27632-10 | More Info |
| SR 16832 | A dual-site covalent antagonist of PPARγ; inhibits MRL20-induced all… | 25 mg | 27632-25 | More Info |
| SR 16832 | A dual-site covalent antagonist of PPARγ; inhibits MRL20-induced all… | 5 mg | 27632-5 | More Info |
| SR 1824 | A non-agonist PPARγ ligand (Ki = 10 nM) which blocks Cdk5-mediated p… | 1 mg | 11087-1 | More Info |
| SR 1824 | A non-agonist PPARγ ligand (Ki = 10 nM) which blocks Cdk5-mediated p… | 10 mg | 11087-10 | More Info |
| SR 1824 | A non-agonist PPARγ ligand (Ki = 10 nM) which blocks Cdk5-mediated p… | 25 mg | 11087-25 | More Info |
| SR 1824 | A non-agonist PPARγ ligand (Ki = 10 nM) which blocks Cdk5-mediated p… | 5 mg | 11087-5 | More Info |
| SR 18292 | An inhibitor of PGC-1α, increases acetylation of PGC-1α; decre… | 1 mg | 22084-1 | More Info |
| SR 18292 | An inhibitor of PGC-1α, increases acetylation of PGC-1α; decre… | 10 mg | 22084-10 | More Info |
| SR 18292 | An inhibitor of PGC-1α, increases acetylation of PGC-1α; decre… | 25 mg | 22084-25 | More Info |
| SR 18292 | An inhibitor of PGC-1α, increases acetylation of PGC-1α; decre… | 5 mg | 22084-5 | More Info |
| SR 1903 | A modulator of RORγ and LXR receptors; an inverse agonist of ROR&gam… | 1 mg | 28253-1 | More Info |
| SR 1903 | A modulator of RORγ and LXR receptors; an inverse agonist of ROR&gam… | 10 mg | 28253-10 | More Info |
| SR 1903 | A modulator of RORγ and LXR receptors; an inverse agonist of ROR&gam… | 5 mg | 28253-5 | More Info |
| SR 202 | An antagonist of troglitazone-induced PPARγ transcriptional activity… | 1 mg | 21846-1 | More Info |
| SR 202 | An antagonist of troglitazone-induced PPARγ transcriptional activity… | 5 mg | 21846-5 | More Info |
| SR 2211 | Selectively binds RORγ (Ki = 105 nM), acting as an inverse agonist o… | 1 mg | 11972-1 | More Info |
| SR 2211 | Selectively binds RORγ (Ki = 105 nM), acting as an inverse agonist o… | 10 mg | 11972-10 | More Info |
| SR 2211 | Selectively binds RORγ (Ki = 105 nM), acting as an inverse agonist o… | 5 mg | 11972-5 | More Info |
| SR 2595 | An inverse agonist of PPARγ (IC50 = 30 nM) that represses both trans… | 1 mg | 18291-1 | More Info |
| SR 2595 | An inverse agonist of PPARγ (IC50 = 30 nM) that represses both trans… | 10 mg | 18291-10 | More Info |
| SR 2595 | An inverse agonist of PPARγ (IC50 = 30 nM) that represses both trans… | 5 mg | 18291-5 | More Info |
| SR 27897 | A nonpeptide CCK receptor antagonist; selectively binds to CCK1 receptors… | 10 mg | 28511-10 | More Info |
| SR 27897 | A nonpeptide CCK receptor antagonist; selectively binds to CCK1 receptors… | 25 mg | 28511-25 | More Info |
| SR 27897 | A nonpeptide CCK receptor antagonist; selectively binds to CCK1 receptors… | 5 mg | 28511-5 | More Info |
| SR 27897 | A nonpeptide CCK receptor antagonist; selectively binds to CCK1 receptors… | 50 mg | 28511-50 | More Info |
| SR 3029 | An inhibitor of CK1δ and CK1ε (IC50s = 44 and 260 nM, respec… | 10 mg | 27048-10 | More Info |
| SR 3029 | An inhibitor of CK1δ and CK1ε (IC50s = 44 and 260 nM, respec… | 25 mg | 27048-25 | More Info |
| SR 3029 | An inhibitor of CK1δ and CK1ε (IC50s = 44 and 260 nM, respec… | 5 mg | 27048-5 | More Info |
| SR 318 | A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, r… | 1 mg | 34233-1 | More Info |
| SR 318 | A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, r… | 10 mg | 34233-10 | More Info |
| SR 318 | A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, r… | 25 mg | 34233-25 | More Info |
| SR 318 | A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, r… | 5 mg | 34233-5 | More Info |
| SR 3335 | A selective inverse agonist of RORα, competitively inhibiting the bi… | 1 mg | 12072-1 | More Info |
| SR 3335 | A selective inverse agonist of RORα, competitively inhibiting the bi… | 10 mg | 12072-10 | More Info |
| SR 3335 | A selective inverse agonist of RORα, competitively inhibiting the bi… | 25 mg | 12072-25 | More Info |
| SR 3335 | A selective inverse agonist of RORα, competitively inhibiting the bi… | 5 mg | 12072-5 | More Info |
| SR 3576 | A JNK3 inhibitor (IC50 = 7 nM); selective for JNK3 over JNK1 and p38 MAP k… | 1 mg | 20215-1 | More Info |
| SR 3576 | A JNK3 inhibitor (IC50 = 7 nM); selective for JNK3 over JNK1 and p38 MAP k… | 5 mg | 20215-5 | More Info |
| SR 3677 | A potent inhibitor of ROCK2 and ROCK1 in enzyme and cell-based assays (IC5… | 1 mg | 16708-1 | More Info |
| SR 3677 | A potent inhibitor of ROCK2 and ROCK1 in enzyme and cell-based assays (IC5… | 10 mg | 16708-10 | More Info |
CAYMAN CHEMICAL COMPANY
CAYMAN CHEMICAL COMPANY
1180 East Ellsworth Road
Ann Arbor MI 48108
P: (734) 971-3335
P: (800) 364-9897 (USA & Canada only)
F: (734) 971-3640
Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com
http://www.caymanchem.com
Return to Profile